Opportunity ID: 270088

General Information

Document Type: Grants Notice
Funding Opportunity Number: RFA-HL-15-026
Funding Opportunity Title: Human Cellular Models for Predicting Individual Responses to Cystic Fibrosis Transmembrane Conductance Regulator- Directed Therapeutics (R41)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
Expected Number of Awards:
Assistance Listings: 93.838 — Lung Diseases Research
Cost Sharing or Matching Requirement: No
Version: Synopsis 1
Posted Date: Dec 03, 2014
Last Updated Date:
Original Closing Date for Applications: Nov 09, 2015
Current Closing Date for Applications: Nov 09, 2015
Archive Date: Dec 10, 2015
Estimated Total Program Funding:
Award Ceiling: $350,000
Award Floor:

Eligibility

Eligible Applicants: Special district governments
Public and State controlled institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
City or township governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Native American tribal organizations (other than Federally recognized tribal governments)
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Public housing authorities/Indian housing authorities
County governments
State governments
Native American tribal governments (Federally recognized)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. A small business concern is one that, at the time of award of Phase I and Phase II, meets all of the following criteria:

1. Is organized for profit, with a place of business located in the United States, which operates primarily within the United States or which makes a significant contribution to the United States economy through payment of taxes or use of American products, materials or labor;

2. Is in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative, except that where the form is a joint venture, there must be less than 50 percent participation by foreign business entities in the joint venture;

3.
i. SBIR and STTR. Be a concern which is more than 50% directly owned and controlled by one or more individuals (who are citizens or permanent resident aliens of the United States), other business concerns (each of which is more than 50% directly owned and controlled by individuals who are citizens or permanent resident aliens of the United States), or any combination of these; OR
ii. SBIR-only. Be a concern which is more than 50% owned by multiple venture capital operating companies, hedge funds, private equity firms, or any combination of these. No single venture capital operating company, hedge fund, or private equity firm may own more than 50% of the concern; OR
iii. SBIR and STTR. Be a joint venture in which each entity to the joint venture must meet the requirements set forth in paragraph 3 (i) or 3 (ii) of this section. A joint venture that includes one or more concerns that meet the requirements of paragraph (ii) of this section must comply with § 121.705(b) concerning registration and proposal requirements.
4. Has, including its affiliates, not more than 500 employees.

Additional Information

Agency Name: National Institutes of Health
Description: This program will support the technical development and validation of novel in vitro human cell-based tools for predicting the responses of individual patients to cystic fibrosis transmembrane conductance regulator (CFTR)-directed therapies for cystic fibrosis (CF) lung disease. NHLBI anticipates that outcomes of successful STTR projects will help attract strategic partners or investors to support ultimate commercialization of a personalized medicine platform that could accelerate translation of CFTR-directed therapy in patients with CF lung disease.
Link to Additional Information: http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-15-026.html
Grantor Contact Information: If you have difficulty accessing the full announcement electronically, please contact:

NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email:FBOWebmaster@OD.NIH.GOV

Version History

Version Modification Description Updated Date

Related Documents

Packages

Agency Contact Information: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

Email: FBOWebmaster@OD.NIH.GOV

Who Can Apply: Organization Applicants

Assistance Listing Number Competition ID Competition Title Opportunity Package ID Opening Date Closing Date Actions
FORMS-C FORMS-C PKG00210403 Jan 09, 2015 Nov 09, 2015 View

Package 1

Mandatory forms

270088 RR_SF424_2_0-2.0.pdf

270088 SBIR_STTR_Information_1_1-1.1.pdf

270088 RR_KeyPersonExpanded_2_0-2.0.pdf

270088 RR_OtherProjectInfo_1_3-1.3.pdf

270088 RR_Budget_1_3-1.3.pdf

270088 RR_SubawardBudget30_1_3-1.3.pdf

270088 PerformanceSite_2_0-2.0.pdf

270088 PHS398_ResearchPlan_2_0-2.0.pdf

270088 PHS398_CoverPageSupplement_2_0-2.0.pdf

Optional forms

270088 PlannedReport-1.0.pdf

270088 PHS398_CumulativeInclusionReport-1.0.pdf

2025-07-09T20:43:30-05:00

Share This Post, Choose Your Platform!

About the Author: